Work

BRAF V600 mutant colorectal cancer (CRC) expansion cohort from the phase I/II clinical trial of BRAF inhibitor dabrafenib (GSK2118436) plus MEK inhibitor trametinib (GSK1120212).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.3528

Authors: Ryan Bruce Corcoran, Gerald Steven Falchook, Jeffrey R. Infante, Omid Hamid, Wells A. Messersmith, Eunice Lee Kwak, David P. Ryan, Razelle Kurzrock, Adrienne A Brenner, Jennifer Luan, Peng Sun, Alicia J Allred, Shonda M Little, Kiran Patel, Scott Kopetz, Alan Paul Venook

Institutions: Massachusetts General Hospital, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, Angeles Clinic and Research Institute, University of Colorado Anschutz, University of California, San Francisco, GlaxoSmithKline (United States)

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2967558598

Cites:

Cited by: 20

Related to: 10